UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars

Targeted oncology, 2017-10, Vol.12 (5), p.599-610

2017

Volltextzugriff (PDF)

Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients

Cancer science, 2011-02, Vol.102 (2), p.478-483

2011

Volltextzugriff (PDF)

Working with Older Adults Scale: Application of the Theory of Planned Behavior

The Gerontologist, 2020-08, Vol.60 (6), p.e428-e437

2020

Volltextzugriff (PDF)

Decoding of Emotion through Facial Expression, Prosody and Verbal Content in Children and Adolescents with Asperger's Syndrome

Journal of autism and developmental disorders, 2006-08, Vol.36 (6), p.769-777

2006

Volltextzugriff (PDF)

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors

Journal of clinical oncology, 2015-03, Vol.33 (9), p.1060-1066

2015

Volltextzugriff (PDF)

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Journal of clinical oncology, 2008-10, Vol.26 (29), p.4708-4713

2008

Volltextzugriff (PDF)

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

Cancer chemotherapy and pharmacology, 2010-07, Vol.66 (2), p.357-371

2010

Volltextzugriff (PDF)

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

BMC cancer, 2013-03, Vol.13 (1), p.152-152, Article 152

2013

Volltextzugriff (PDF)

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Clinical cancer research, 2020-03, Vol.26 (5), p.1025-1033

2020

Volltextzugriff (PDF)

The Impact of Maltreatment History and the Presence of Individual, Familial, and Communal Protective Factors on College Adjustment

Journal of aggression, maltreatment & trauma, 2022-09, Vol.31 (8), p.1090-1107

2022

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

Journal of clinical oncology, 2009-07, Vol.27 (21), p.3557-3565

2009

Volltextzugriff (PDF)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

British journal of cancer, 2018, Vol.118 (2), p.153-161

2018

Volltextzugriff (PDF)

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Clinical cancer research, 2012-09, Vol.18 (17), p.4820-4829

2012

Volltextzugriff (PDF)

VEGF‐Targeted Therapy: Therapeutic Potential and Recent Advances

The oncologist (Dayton, Ohio), 2005-06, Vol.10 (6), p.382-391

Rosen, Lee S.

2005

Volltextzugriff (PDF)

Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

Cancer, 2012-12, Vol.118 (23), p.5903-5911

2012

Volltextzugriff (PDF)

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer

Clinical cancer research, 2017-04, Vol.23 (8), p.1910-1919

2017

Volltextzugriff (PDF)

Tivantinib (ARQ 197), a Selective Inhibitor of MET, in Patients With Microphthalmia Transcription Factor―Associated Tumors: Results of a Multicenter Phase 2 Trial

Cancer, 2012-12, Vol.118 (23), p.5894-5902

2012

Volltextzugriff (PDF)

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

Cancer, 2015-05, Vol.121 (9), p.1405-1413

2015

Volltextzugriff (PDF)

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-06, Vol.15 (12), p.4213-4219

2009

Volltextzugriff (PDF)

The Impact of Protective Factors on Posttraumatic Growth for College Student Survivors of Childhood Maltreatment

Journal of aggression, maltreatment & trauma, 2017-08, Vol.26 (7), p.756-771

2017

Volltextzugriff (PDF)

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

Journal of clinical oncology, 2003-08, Vol.21 (16), p.3150-3157

2003

Volltextzugriff (PDF)

A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors

Investigational new drugs, 2020-02, Vol.38 (1), p.120-130

2020

Volltextzugriff (PDF)

Endoglin for Targeted Cancer Treatment

Current oncology reports, 2014-02, Vol.16 (2), p.365-365, Article 365

2014

Volltextzugriff (PDF)

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Clinical cancer research, 2013-11, Vol.19 (21), p.6020-6029

2013

Volltextzugriff (PDF)

1 – 25 von 1.721

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.464)
Mit Volltextzugriff
(1.433)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(763)
EZB Electronic Journals Library
(744)
Journals@Ovid Ovid Full Text
(716)
IngentaConnect
(639)
NUS Single-Journal Subscriptions
(558)
Elsevier ScienceDirect Journals Complete
(329)
Wiley-Blackwell Journals
(237)
IngentaConnect Journals
(220)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(145)
Wiley Online Library Full Collection 2018
(133)
SpringerLink_现刊
(123)
JSTOR
(96)
Ebook Central Perpetual and DDA
(90)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(87)
eBooks on EBSCOhost
(87)
Oxford journals
(80)
Nexis Uni
(72)
Oxford Journals 2020 Medicine
(68)
Nature Journals
(62)
SAGE Journals
(55)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars

Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients

Working with Older Adults Scale: Application of the Theory of Planned Behavior

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

Decoding of Emotion through Facial Expression, Prosody and Verbal Content in Children and Adolescents with Asperger's Syndrome

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

The Impact of Maltreatment History and the Presence of Individual, Familial, and Communal Protective Factors on College Adjustment

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

VEGF‐Targeted Therapy: Therapeutic Potential and Recent Advances

Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer

Tivantinib (ARQ 197), a Selective Inhibitor of MET, in Patients With Microphthalmia Transcription Factor―Associated Tumors: Results of a Multicenter Phase 2 Trial

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

The Impact of Protective Factors on Posttraumatic Growth for College Student Survivors of Childhood Maltreatment

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors

Endoglin for Targeted Cancer Treatment

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Suchergebnisse filtern